Hepatitis B core protein as a therapeutic target
نویسندگان
چکیده
منابع مشابه
Significance of Hepatitis B Core Antibody as the Only Marker of Hepatitis B Virus Infection in High Risk Patients
Background and Objective: Presence of hepatitis B core antibody (anti-HBc) in the absence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) is defined, as isolated anti-HBc. little is known about the clinical significance of the isolated anti-HBc in hepatitis B virus (HBV) infections. The aim of this study was to assess the significance of anti-HBc as the onl...
متن کاملP 86: CD166 as a Therapeutic Target in Autoimmune Diseases
About 3 decades ago CD6 identified as one of the first antigens expresses on the majority of T cells and a subset of B cells. CD6 regulates cellular adhesion migration across the endothelial and epithelial cells. In recent years researches indicate its role in pathogenesis of autoimmune diseases. Many researches have been done in recent years to block CD6 by CD6 mono clonal antibodies, IOR-T1 a...
متن کاملProtein kinase C as a therapeutic target.
The recognition of protein kinase C (PKC) as the long soughtafter receptor for the tumor-promoting phorbol esters established the potential role of PKC in carcinogenesis and as a potentially important target for cancer therapeutics (1, 2). PKC is a family of serine/threonine kinases that regulate a variety of cell functions including proliferation, gene expression, cell cycle, differentiation, ...
متن کاملCore as a Novel Viral Target for Hepatitis C Drugs
Hepatitis C virus (HCV) infects over 130 million people worldwide and is a major cause of liver disease. No vaccine is available. Novel specific drugs for HCV are urgently required, since the standard-of-care treatment of pegylated interferon combined with ribavirin is poorly tolerated and cures less than half of the treated patients. Promising, effective direct-acting drugs currently in the cl...
متن کاملB cell signalling as therapeutic target.
B iological therapy holds the promise of specificity of intervention. Recent progress in development of such therapies has proved that rational targeting can lead to clinical benefit. B cells pose an attractive target in autoimmunity. Approaches currently being tested lead to depletion of B cells or at least circulating B cells. Such therapies appear remarkably benign, but the effects of repeat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Opinion on Therapeutic Targets
سال: 2017
ISSN: 1472-8222,1744-7631
DOI: 10.1080/14728222.2017.1397134